Potential non-glycoprotein IIb/IIIa effects of abciximab

American Heart Journal

Volumn 138, Issue 1 II, 1999, Pages s1-

  Coller, B S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CD11B ANTIGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN RECEPTOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL ADHESION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; GRANULOCYTE; HUMAN; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RESTENOSIS; SICKLE CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032790988     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.99078     Document Type: Conference Paper

References (50)

1. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-71.
2. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, et al. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991;614:193-213.
3. Charo IF, Fitzgerald LA, Steiner B, Rall SC Jr, Bekeart LS, Phillips DR. Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci USA 1986;83:8351-6.
4. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab Patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
5. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol 1988;141:2656-60.
6. Leahy DJ. Implications of atomic-resolution structures for cell adhesion. Ann Rev Cell Dev Biol 1997;13:363-93.
7. Lin EK, Ratnikov BI, Tsai PM, Gonzalez ER, McDonald S, Pelletier AJ, et al. Evidence that the integrin beta3 and beta5 subunits contain a metal ion-dependent adhesion site-like motif but lack an I domain. J Biol Chem 1997;272:14236-43.
8. Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JC. Ligand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit. J Biol Chem 1996;271:21978-84.
9. Plescia J, Conte MS, VanMeter G, Ambrosini G, Altieri DC. Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem 1998;273:20372-7.
10. Winn R, Vedder N, Ramamoorthy C, Sharar S, Harlan J. Endothelial and leukocyte adhesion molecules in inflammation and disease. Blood Coagul Fibrinolysis 1998;9(suppl):S17-S23.
11. Zhou L, Lee DH, Plescia J, Lau CY, Altieri DC. Differential ligand binding specificities of recombinant CD11b/CD18 integrin Idomain. J Biol Chem 1994;269:17075-9.
12. Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1- fibrinogen recognition. Proc Natl Acad Sci USA 1995;92:1505-9.
13. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 1993;1201-43.
14. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998;95:10134-9.
15. Simon DI, Chen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Markedly reduced neointimal thickening in Mac-1 (CD11b/CD18)-deficient mice after carotid artery dilation and endothelial denudation [abstract]. Circulation 1998;98(suppl): I-238.
16. Osterud B. A global view on the role of monocytes and platelets in atherogenesis. Thromb Res 1997;85:1-22.
17. Meisel SR, Shapiro H, Radnay J, Neuman Y, Khaskia AR, Gruener N, et al. Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol 1998;31:120-5.
18. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.
19. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 1994;25:869-75.
20. Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 1998;102:1301-10.
21. Jordan RE, Wagner CL, Mascelli M, Treacy G, Nedelman MA, Woody JN, et al. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, editor. Adhesion receptors as therapeutic targets. Boca Raton (FL): CRC Press; 1996. p. 281-305.
22. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864-8.
23. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
24. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
25. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
26. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996;8:724-30.
27. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR, Schwartz RS, et al. Selective αVβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αVβ3 and osteopontin expression during neointima formation. Cardiovasc Res 1997;36:408-28.
28. Stouffer GA, Hu Z, Sajid M, Li H, Jin G, Nakada MT, Hanson SR, et al. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 1998;97:907-15.
29. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 1998;89:1-21.
30. Bennett JS, Chan C, Vilaire G, Mousa SA, DeGrado WF. Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Bio Chem 1997;272:8137-40.
31. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the prevention of ischemic complications trial. Am J Cardiol 1995;75:559-62.
32. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet GPIIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7.
33. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-74.
34. Byzova TV, Plow EF. Networking in the hemostatic system: integrin alphaIIbbeta3 binds prothrombin and influences its activation. J Biol Chem 1997;272:27183-8.
35. Byzova TV, Plow EF Activation of αVβ3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998;143:2081-92
36. Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 1996;3:118-24.
37. Varner JA, Nakada M, Jordan R, Coller BS. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab abciximab; ReoPro™. Angiogenesis 1999. In press.
38. 2 [abstract]. Blood 1998;92(suppl):497a.
39. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995;77:1129-35.
40. Slepian MJ, Massia SP, Dehdashti B, Fritz A, Whitesell L. Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation 1998;97:1818-27.
41. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, et al. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125-34.
42. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994;90:2203-6.
43. van der Zee R, Murohara T, Passeri J, Kearney M, Cheresh DA, Isner JM. Reduced intimal thickening following αVβ3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes Commun 1998;6:371-9.
44. Le Breton H, Rabbani R, Plow EF, Mousa SA, Lincoff AM, Forudi F, et al. The role of integrins glycoprotein (GP) IIb/IIIa and αVβ3 (the vitronectin receptor) in a guinea-pig model of restenosis [abstract]. Circulation 1996;94:I-517.
45. Topol EJ, Califf RM, Weismann HF, Ellis SG, Tcheng JE, Worley S, et al, on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
46. Simoons ML, de Boer MJ, van den Brand MJ, van Mittenburg AJ, Hoorntje JC, Hegndrickx GR, et al, the European Cooperative study group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
47. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
48. Cura FA, L'Allier L, Sapp S, Lincoff AM, Ellis SG, Topol EJ, for the EPISTENT Investigators. Comparison of the protection against restenosis afforded by stenting or abciximab [abstract]. J Am Coll Cardiol 1999;33:IIA.
49. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-35.
50. Schwartz SM. Perspectives series: cell adhesion in vascular biology: smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997;99:2814-6.